PE20260005A1 - Compuestos coagonistas de gip/glp1 - Google Patents
Compuestos coagonistas de gip/glp1Info
- Publication number
- PE20260005A1 PE20260005A1 PE2025001612A PE2025001612A PE20260005A1 PE 20260005 A1 PE20260005 A1 PE 20260005A1 PE 2025001612 A PE2025001612 A PE 2025001612A PE 2025001612 A PE2025001612 A PE 2025001612A PE 20260005 A1 PE20260005 A1 PE 20260005A1
- Authority
- PE
- Peru
- Prior art keywords
- coagonist
- glp1
- gip
- compounds
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702072P | 2018-07-23 | 2018-07-23 | |
| US201862730563P | 2018-09-13 | 2018-09-13 | |
| US201862740596P | 2018-10-03 | 2018-10-03 | |
| PCT/US2019/042822 WO2020023386A1 (en) | 2018-07-23 | 2019-07-22 | Gip/glp1 co-agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20260005A1 true PE20260005A1 (es) | 2026-01-06 |
Family
ID=67620523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2025001612A PE20260005A1 (es) | 2018-07-23 | 2019-07-22 | Compuestos coagonistas de gip/glp1 |
| PE2021000081A PE20211637A1 (es) | 2018-07-23 | 2019-07-22 | Compuestos coagonistas de gip/glp1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000081A PE20211637A1 (es) | 2018-07-23 | 2019-07-22 | Compuestos coagonistas de gip/glp1 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11084861B2 (https=) |
| EP (2) | EP4549454A3 (https=) |
| JP (3) | JP6920559B2 (https=) |
| KR (3) | KR20240051304A (https=) |
| CN (2) | CN119504975A (https=) |
| AU (2) | AU2019311000B2 (https=) |
| BR (1) | BR112020026671A2 (https=) |
| CA (3) | CA3107345C (https=) |
| CL (1) | CL2021000158A1 (https=) |
| CO (1) | CO2021000453A2 (https=) |
| CR (1) | CR20210040A (https=) |
| DO (1) | DOP2021000016A (https=) |
| EC (1) | ECSP21004913A (https=) |
| FI (1) | FI3827015T3 (https=) |
| IL (1) | IL279827A (https=) |
| JO (2) | JOP20210016A1 (https=) |
| MA (1) | MA53382A (https=) |
| MX (1) | MX2021000793A (https=) |
| MY (1) | MY197569A (https=) |
| PE (2) | PE20260005A1 (https=) |
| PH (1) | PH12021550154A1 (https=) |
| SA (1) | SA521421080B1 (https=) |
| SG (1) | SG11202100128UA (https=) |
| TW (3) | TWI863239B (https=) |
| UA (1) | UA129537C2 (https=) |
| WO (1) | WO2020023386A1 (https=) |
| ZA (3) | ZA202100235B (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102455171B1 (ko) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| CN119499352A (zh) * | 2018-07-23 | 2025-02-25 | 伊莱利利公司 | 使用gip/glp1共激动剂用于糖尿病的方法 |
| KR20240051304A (ko) * | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| KR102812908B1 (ko) | 2019-08-19 | 2025-05-28 | 일라이 릴리 앤드 캄파니 | 인크레틴 유사체의 제조 방법 |
| MX2022006861A (es) | 2019-12-04 | 2022-07-11 | Scripps Research Inst | Agonistas del receptor glp2 y metodos de uso. |
| IL294955A (en) * | 2020-01-23 | 2022-09-01 | Lilly Co Eli | Cobalt-agonist gip/glp1 compounds |
| EP4110800A1 (en) | 2020-03-06 | 2023-01-04 | Sanofi | Peptides as selective gip receptor agonists |
| WO2021198229A1 (en) | 2020-03-31 | 2021-10-07 | Antaros Medical Ab | Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| US20230346961A1 (en) | 2020-07-22 | 2023-11-02 | Novo Nordisk A/S | Glp-1 and gip receptor co-agonists |
| EP4185607A1 (en) | 2020-07-22 | 2023-05-31 | Novo Nordisk A/S | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
| PE20231309A1 (es) | 2020-10-17 | 2023-08-24 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip |
| AR124295A1 (es) | 2020-12-18 | 2023-03-15 | Lilly Co Eli | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos |
| CA3200209A1 (en) * | 2020-12-22 | 2022-06-30 | Eli Lilly And Company | Therapeutic peptide formulations |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| CN117320740A (zh) * | 2021-02-17 | 2023-12-29 | 伊莱利利公司 | Gip/glp1双重激动剂治疗方法 |
| TWI837615B (zh) * | 2021-03-23 | 2024-04-01 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
| US12215133B2 (en) | 2021-03-25 | 2025-02-04 | Brightgene Bio-Medical Technology Co., Ltd. | GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use |
| WO2022199629A1 (zh) * | 2021-03-25 | 2022-09-29 | 博瑞生物医药（苏州）股份有限公司 | Gip和glp-1的双受体激动剂、药物组合物及用途 |
| CN115181173A (zh) * | 2021-04-02 | 2022-10-14 | 深圳市健元医药科技有限公司 | 一种Tirzepatide的制备方法 |
| AU2022269659B2 (en) * | 2021-05-07 | 2025-04-10 | Eli Lilly And Company | Erodible tablet |
| CN113332416B (zh) * | 2021-05-17 | 2022-02-22 | 宁波大学 | 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用 |
| IL306122B2 (en) * | 2021-05-28 | 2026-01-01 | Guangdong Raynovent Biotech Co Ltd | Preparation and use of polypeptide |
| EP4345105A4 (en) * | 2021-06-01 | 2025-04-23 | Nanjing Zhihe Medicine Technology Co., Ltd | Polypeptide derivative with dual targeted activation of GLP-1R and GIPR, manufacturing process therefor and use thereof |
| KR20240032010A (ko) | 2021-06-09 | 2024-03-08 | 더 스크립스 리서치 인스티튜트 | 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법 |
| CN115594752A (zh) * | 2021-07-07 | 2023-01-13 | 成都奥达生物科技有限公司（Cn） | 一种长效双激动剂化合物 |
| KR20240055069A (ko) | 2021-09-06 | 2024-04-26 | 사노피 | 효력있는 선택적 gip 수용체 작용제로서의 신규 펩티드 |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| AU2022392980B2 (en) * | 2021-11-19 | 2025-12-18 | Jiangsu Deyuan Pharmaceutical Co., Ltd. | Stapled peptide and use thereof |
| CN118234742A (zh) * | 2021-12-01 | 2024-06-21 | 江苏恒瑞医药股份有限公司 | Glp-1和gip受体双重激动剂的药物组合物及其用途 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| US20260055142A1 (en) * | 2022-04-07 | 2026-02-26 | Guangdong Raynovent Biotech Co., Ltd. | Pharmaceutical use of polypeptide in preparation of drugs for treating and/or preventing diabetes and obesity and related diseases thereof |
| CN119907661A (zh) * | 2022-07-05 | 2025-04-29 | G2G生物公司 | 含有司美格鲁肽或其药学上可接受的盐的缓释微球制剂及其制备方法 |
| EP4556487A1 (en) * | 2022-07-13 | 2025-05-21 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1/gip dual agonist, and preparation method therefor and use thereof |
| JP2025530743A (ja) | 2022-08-29 | 2025-09-17 | イーライ リリー アンド カンパニー | 経口投与のための組成物 |
| CN119894921A (zh) * | 2022-09-15 | 2025-04-25 | 伊莱利利公司 | Gip和glp-1双重激动剂化合物 |
| KR20250110330A (ko) * | 2022-11-21 | 2025-07-18 | 일라이 릴리 앤드 캄파니 | Gip/glp1 이중 효능제의 제조 방법 |
| US20240270821A1 (en) | 2023-01-31 | 2024-08-15 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| KR20260022948A (ko) | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| CN121464152A (zh) * | 2023-06-30 | 2026-02-03 | 株式会社汇恩斯拉布 | 以glp类似物为有效成分的用于预防或治疗肥胖的药物组合物 |
| WO2025087353A1 (zh) * | 2023-10-26 | 2025-05-01 | 齐鲁制药有限公司 | 具有多重激动活性的多肽及其应用 |
| TW202529796A (zh) * | 2023-11-22 | 2025-08-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1r/gipr雙標靶激動劑在製備動物藥的用途 |
| TW202540155A (zh) | 2023-11-30 | 2025-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| CN117624333A (zh) * | 2023-12-05 | 2024-03-01 | 江苏师范大学 | 一类GLP-1受体、glucagon受体和GIP受体三激动多肽化合物及其应用 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| TW202542174A (zh) * | 2023-12-29 | 2025-11-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1/gip雙激動劑的固相合成方法 |
| WO2025147633A2 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Gip/glp-1 co-agonists and their associated prodrugs |
| TW202535912A (zh) * | 2024-01-12 | 2025-09-16 | 大陸商杭州中美華東製藥有限公司 | 長效glp-1/gip雙激動劑的鼻腔遞送藥物組合物 |
| WO2025149039A1 (zh) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | 长效glp-1/gip双激动剂的药物组合物 |
| WO2025161155A1 (zh) * | 2024-02-04 | 2025-08-07 | 内蒙古博睿精创科技有限公司 | 一种长效glp-1多肽化合物、组合物及其应用 |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
| WO2025264785A1 (en) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
| WO2025264809A1 (en) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
| WO2025264776A1 (en) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
| JP2026031900A (ja) * | 2024-07-24 | 2026-02-25 | イーライ リリー アンド カンパニー | Ｆｃ－アシル化ポリペプチドコンジュゲート |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2694095T3 (en) * | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
| IN2014MN02304A (https=) * | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| PE20150863A1 (es) * | 2012-06-21 | 2015-06-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| JP2016521253A (ja) | 2013-03-15 | 2016-07-21 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 持続性作用を有するプロドラッグ |
| KR102272671B1 (ko) | 2013-05-02 | 2021-07-06 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| CN108271356A (zh) * | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| TWI582109B (zh) * | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| WO2016198604A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists |
| US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| WO2017112897A1 (en) * | 2015-12-22 | 2017-06-29 | Engineered Controls International, Llc | Noise reducing filler valve |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| KR20240051304A (ko) * | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
-
2019
- 2019-07-22 KR KR1020247011528A patent/KR20240051304A/ko active Pending
- 2019-07-22 TW TW112115808A patent/TWI863239B/zh active
- 2019-07-22 JP JP2020545276A patent/JP6920559B2/ja active Active
- 2019-07-22 KR KR1020217007140A patent/KR20210031533A/ko not_active Ceased
- 2019-07-22 CA CA3107345A patent/CA3107345C/en active Active
- 2019-07-22 MA MA053382A patent/MA53382A/fr unknown
- 2019-07-22 FI FIEP19753218.7T patent/FI3827015T3/fi active
- 2019-07-22 MY MYPI2021000294A patent/MY197569A/en unknown
- 2019-07-22 TW TW108125887A patent/TWI735917B/zh active
- 2019-07-22 CN CN202411661780.4A patent/CN119504975A/zh active Pending
- 2019-07-22 CN CN201980049095.7A patent/CN112469731B/zh active Active
- 2019-07-22 TW TW110125507A patent/TWI810606B/zh active
- 2019-07-22 EP EP25155884.7A patent/EP4549454A3/en active Pending
- 2019-07-22 MX MX2021000793A patent/MX2021000793A/es unknown
- 2019-07-22 SG SG11202100128UA patent/SG11202100128UA/en unknown
- 2019-07-22 BR BR112020026671-0A patent/BR112020026671A2/pt unknown
- 2019-07-22 CR CR20210040A patent/CR20210040A/es unknown
- 2019-07-22 UA UAA202100210A patent/UA129537C2/uk unknown
- 2019-07-22 US US16/518,468 patent/US11084861B2/en active Active
- 2019-07-22 CA CA3178366A patent/CA3178366C/en active Active
- 2019-07-22 JO JOP/2021/0016A patent/JOP20210016A1/ar unknown
- 2019-07-22 CA CA3294907A patent/CA3294907A1/en active Pending
- 2019-07-22 WO PCT/US2019/042822 patent/WO2020023386A1/en not_active Ceased
- 2019-07-22 PE PE2025001612A patent/PE20260005A1/es unknown
- 2019-07-22 AU AU2019311000A patent/AU2019311000B2/en active Active
- 2019-07-22 EP EP19753218.7A patent/EP3827015B1/en active Active
- 2019-07-22 PE PE2021000081A patent/PE20211637A1/es unknown
- 2019-07-22 KR KR1020217002322A patent/KR102351313B1/ko active Active
-
2020
- 2020-12-29 IL IL279827A patent/IL279827A/en unknown
-
2021
- 2021-01-13 ZA ZA2021/00235A patent/ZA202100235B/en unknown
- 2021-01-19 CO CONC2021/0000453A patent/CO2021000453A2/es unknown
- 2021-01-20 DO DO2021000016A patent/DOP2021000016A/es unknown
- 2021-01-20 CL CL2021000158A patent/CL2021000158A1/es unknown
- 2021-01-20 PH PH12021550154A patent/PH12021550154A1/en unknown
- 2021-01-21 SA SA521421080A patent/SA521421080B1/ar unknown
- 2021-01-22 EC ECSENADI20214913A patent/ECSP21004913A/es unknown
- 2021-07-02 US US17/366,998 patent/US12252524B2/en active Active
- 2021-07-26 JP JP2021121693A patent/JP7626530B2/ja active Active
- 2021-08-16 ZA ZA2021/05821A patent/ZA202105821B/en unknown
- 2021-09-01 ZA ZA2021/06369A patent/ZA202106369B/en unknown
-
2023
- 2023-05-02 AU AU2023202709A patent/AU2023202709A1/en not_active Abandoned
- 2023-09-08 JP JP2023145813A patent/JP2023171775A/ja active Pending
-
2024
- 2024-10-18 US US18/919,541 patent/US20250051415A1/en active Pending
-
2025
- 2025-08-03 JO JOJO/P/2025/0198A patent/JOP20250198A1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20260005A1 (es) | Compuestos coagonistas de gip/glp1 | |
| CL2021003419A1 (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| PE20170954A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| ECSP23095307A (es) | Agonista del receptor de glp-1 y composición y uso del mismo | |
| CL2022001529A1 (es) | Nuevos derivados de metilquinazolinona | |
| CL2019001552A1 (es) | Agonistas duales acilados de glp-1/glp-2. | |
| MX2018011676A (es) | Compuestos organicos. | |
| CL2024002499A1 (es) | Compuestos como agonistas de glp-1r | |
| AR069136A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos | |
| MX2025014917A (es) | Conjugados del peptido de fusion peptido similar al glucagon 1 (glp-1) acoplado al peptido tirosina tirosina y usos de estos | |
| CR20120242A (es) | Composición farmacéutica que comprende un agonista de glp-1, y metionina | |
| DOP2025000110A (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| CL2021003342A1 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. | |
| PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| MX2022005415A (es) | Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo. | |
| MX2024008745A (es) | Compuesto derivado de 1,3-benzodioxol y composicion farmaceutica que comprende el mismo. | |
| AR113100A1 (es) | Compuestos que activan la ruta nrf2 | |
| AR125905A1 (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| AR107310A1 (es) | Inhibidores de tetrahidrocarbazol de receptores sirt1 | |
| EP4360645A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A GLP-1 COMPOUND | |
| MX2022005384A (es) | Composiciones azeotropicas o de tipo azeotropo de 2-cloro-3,3,3-trifluoropropeno (hcfo-1233xf) y agua. | |
| AR107282A1 (es) | Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip) | |
| AR119173A1 (es) | Agonistas del receptor del péptido-1 similar al glucagón |